Accueil   Agenda - News   Toutes les news Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study

Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study

 

  • Phase 2a results demonstrate excellent safety profile alongside strong, dose-dependent immune response

  •  First patient enrolled in complementary Phase 2a dose optimization study

 


Lyon, France – December 21st, 2021 – Osivax, a biopharmaceutical company focused on preventing the spread of constantly mutating global infectious diseases, including influenza and coronaviruses, announced today promising results of its Phase 2a clinical trial with OVX836, Osivax’ broad-spectrum influenza vaccine candidate developed using the company’s proprietary oligoDOM® nanoparticle technology platform. Unlike conventional vaccines which target highly mutating surface proteins and need to be updated to match seasonal influenza strains, OVX836 targets the internal nucleoprotein (NP), a highly conserved antigen that is far less susceptible to mutations and would thus provide universal protection.

 

 

Lire le communiqué de presse